| AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ... New England Journal of Medicine 371 (11), 1028-1038, 2014 | 2837 | 2014 |
| Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ... JAMA oncology 1 (5), 582-591, 2015 | 689 | 2015 |
| Serial blood-based analysis of AR-V7 in men with advanced prostate cancer M Nakazawa, C Lu, Y Chen, CJ Paller, MA Carducci, MA Eisenberger, ... Annals of Oncology 26 (9), 1859-1865, 2015 | 185 | 2015 |
| Mechanisms of therapeutic resistance in prostate cancer M Nakazawa, C Paller, N Kyprianou Current oncology reports 19, 1-12, 2017 | 163 | 2017 |
| Androgen receptor splice variants in the era of enzalutamide and abiraterone M Nakazawa, ES Antonarakis, J Luo Hormones and cancer 5, 265-273, 2014 | 137 | 2014 |
| Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond M Nakazawa, N Kyprianou The Journal of steroid biochemistry and molecular biology 166, 84-90, 2017 | 68 | 2017 |
| Genetic alterations detected in cell-free DNA are associated with enzalutamide and abiraterone resistance in castration-resistant prostate cancer S Torquato, A Pallavajjala, A Goldstein, P Valda Toro, JL Silberstein, ... JCO precision oncology 3, 1-14, 2019 | 56 | 2019 |
| Resistance to androgen-pathway drugs in prostate cancer. ES Antonarakis, M Nakazawa, J Luo The New England journal of medicine 371 (23), 2234-2234, 2014 | 45 | 2014 |
| Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC). ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, Y Chen, ... Journal of Clinical Oncology 32 (15_suppl), 5001-5001, 2014 | 39 | 2014 |
| AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC). ES Antonarakis, C Lu, Y Chen, B Luber, H Wang, M Nakazawa, ... Journal of Clinical Oncology 33 (7_suppl), 138-138, 2015 | 36 | 2015 |
| Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer EM Ledet, EF Burgess, AO Sokolova, EB Jaeger, W Hatton, M Moses, ... The Prostate 81 (7), 433-439, 2021 | 35 | 2021 |
| Efficacy of abiraterone and enzalutamide in pre‐and postdocetaxel castration‐resistant prostate cancer: a trial‐level meta‐analysis M Fang, M Nakazawa, ES Antonarakis, C Li Prostate Cancer 2017 (1), 8560827, 2017 | 29 | 2017 |
| Clinical and genomic features of SPOP‐mutant prostate cancer M Nakazawa, M Fang, C H. Marshall, TL Lotan, P Isaacsson Velho, ... The Prostate 82 (2), 260-268, 2022 | 28 | 2022 |
| Detection fidelity of AR mutations in plasma derived cell-free DNA A Goldstein, PV Toro, J Lee, JL Silberstein, M Nakazawa, I Waters, ... Oncotarget 8 (9), 15651, 2017 | 26 | 2017 |
| Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy T Hilal, M Nakazawa, J Hodskins, JL Villano, A Mathew, G Goel, ... BMC cancer 17, 1-8, 2017 | 25 | 2017 |
| Prolonged severe acute respiratory syndrome coronavirus 2 delta variant shedding in a patient with AIDS: case report and review of the literature JL Peters, A Fall, SD Langerman, M El Asmar, M Nakazawa, A Mustapha, ... Open Forum Infectious Diseases 9 (9), ofac479, 2022 | 10 | 2022 |
| Androgen receptor splice variant-7 predicts resistance to enzalutamide in patients with castration-resistant prostate cancer ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ... Cancer Research 74 (19_Supplement), 2910-2910, 2014 | 4 | 2014 |
| AR-V7 splice variant and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC): Overall survival results ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, J Roeser, Y Chen, ... Annals of Oncology 25, v1, 2014 | 4 | 2014 |
| SPOP mutations in prostate cancer: Clinical and genomic features. M Nakazawa, M Fang, P Issacsson Velho, ES Antonarakis Journal of Clinical Oncology 39 (6_suppl), 151-151, 2021 | 3 | 2021 |
| Glutamine antagonist DRP-104 in combination with durvalumab in patients with advanced fibrolamellar carcinoma (FLC) following progression on prior anti-PD (L) 1 therapy. M Nakazawa, Z Kamdar, A Thomas, JN Durham, J Nauroth, H Wang, ... Journal of Clinical Oncology 42 (3_suppl), TPS573-TPS573, 2024 | 1 | 2024 |
